Global Cystic Fibrosis Therapeutic Market

Cystic Fibrosis Therapeutic Comprehensive Study by Type (Medications, Airway Clearance Techniques, Pulmonary Rehabilitation, Surgery), Application (Hospitals, Homecare, Speciality Centres), Route of Administration (Oral, Inhalation), Drug Class (Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, CFTR modulators), Symptoms (Sputum, Wheezing, Exercise Intolerance, Repeated Lung Infections, Inflamed Nasal Passages, Recurrent Sinusitis) Players and Region - Global Market Outlook to 2028

Cystic Fibrosis Therapeutic Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Cystic Fibrosis Therapeutic Market Overview:
Cystic fibrosis (CF) is generally known as an inherited disease that hereby causes severe damage to the lungs, digestive system, as well as some other organs in the body. Cystic fibrosis thereby affects the cells that produce mucus, sweat, as well as digestive juices. These secreted liquids are usually thin and slippery. In people with CF, a defective gene causes secretions to become sticky and thick. Instead of acting as a lubricant, the secretions clog tubes, ducts, and passageways, especially in the lungs and pancreas. The signs and symptoms of cystic fibrosis vary depending on the severity of the condition. Even in the same person, symptoms may get worse or get better over time. Some people may not experience symptoms until they are in their teens or adulthood. An early diagnosis means that treatment can start immediately. There is as such no cure present for cystic fibrosis, but the various treatments can relieve symptoms, reduce complications, and also improve quality of life. Close monitoring and early, aggressive intervention are recommended to slow the progression of CF, which can lead to a longer lifespan. There are a number of CF therapies that can be prescribed to patients for both the lungs and the digestive tract.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Improved Healthcare Infrastructure, Reimbursements, And Initiatives and An Upsurge in The Number of Clinical Trials to Expand Its Target Patient Base with The Existing Drug Portfolio

Market Growth Drivers:
A Rise in Prevalence of Cystic Fibrosis, The Surge in Awareness About Cystic Fibrosis Across the Globe, High Public and Private Healthcare Spending, Availability of Personalized Drug Therapy & Molecular Prosthetics for The Treatment and Increasing Awareness and Better Healthcare Facilities

Challenges:
Introduction of Generic Drugs

Restraints:
High Cost of The Cystic Fibrosis Treatment and Increase in Complexity of Disease

Opportunities:
The Rising Favorable Initiatives Taken by Regional and National Nonprofit Organizations, Growing Focus on Developing Oral Routes of Administration and Increase In R&D Investments Made by Government in The Healthcare Sector

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Genentech, Inc. (United States), Novartis AG (Switzerland), Gilead Sciences, Inc. (United States), Vertex Pharmaceuticals Incorporated (United States), AbbVie Inc. (United States), GlaxoSmithKline Plc. (United Kingdom), Johnson & Johnson (United States), Allergan plc (Ireland), Pharmaxis Ltd. (Australia) and Mylan N.V. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Cystic Fibrosis Therapeutic market by 2028. Considering Market by Route of Administration, the sub-segment i.e. Oral will boost the Cystic Fibrosis Therapeutic market. Considering Market by Drug Class, the sub-segment i.e. Pancreatic Enzyme Supplements will boost the Cystic Fibrosis Therapeutic market. Considering Market by Symptoms, the sub-segment i.e. Sputum will boost the Cystic Fibrosis Therapeutic market.

Latest Market Insights:
On February 27, 2023, AbbVie Inc. and Arrowhead Pharmaceuticals, Inc. formed a strategic alliance to develop and commercialize next-generation CF therapies using Arrowhead's RNA interference (RNAi) platform. This collaboration aims to combine AbbVie's clinical expertise in CF with Arrowhead's innovative RNAi technology to bring new treatment options to CF patients.

On March 11, 2023, Vertex Pharmaceuticals Inc. and Codexis, Inc. announced a collaboration agreement to develop novel CF therapies using Codexis's proprietary enzyme engineering technology. This partnership aims to leverage Codexis's expertise in enzyme engineering to create more effective and targeted CF treatments.

The US Food and Drug Administration had approved Trikafta (elexacaftor / ivacaftor / tezacaftor), which is the first triple combination therapy that is available for the treatment of patients with cystic fibrosis mutation. Trikafta is approved for use in patients 12 years of age and older with cystic fibrosis who have at least one F508del mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, which is an estimated 90% of the cystic fibrosis population. Trikafta also received the Orphan Drug Designation, which provides incentives to support and promote drug development for rare diseases. Drugs approved under accelerated programs are subject to the same approval standards as other FDA approvals.

What Can be Explored with the Cystic Fibrosis Therapeutic Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Cystic Fibrosis Therapeutic Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Cystic Fibrosis Therapeutic
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Cystic Fibrosis Therapeutic market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Cystic Fibrosis Therapeutic market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Cystic Fibrosis Therapeutic, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Medications
  • Airway Clearance Techniques
  • Pulmonary Rehabilitation
  • Surgery
By Application
  • Hospitals
  • Homecare
  • Speciality Centres
By Route of Administration
  • Oral
  • Inhalation

By Drug Class
  • Pancreatic Enzyme Supplements
  • Mucolytic
  • Bronchodilators
  • CFTR modulators

By Symptoms
  • Sputum
  • Wheezing
  • Exercise Intolerance
  • Repeated Lung Infections
  • Inflamed Nasal Passages
  • Recurrent Sinusitis

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. A Rise in Prevalence of Cystic Fibrosis
      • 3.2.2. The Surge in Awareness About Cystic Fibrosis Across the Globe
      • 3.2.3. High Public and Private Healthcare Spending
      • 3.2.4. Availability of Personalized Drug Therapy & Molecular Prosthetics for The Treatment
      • 3.2.5. Increasing Awareness and Better Healthcare Facilities
    • 3.3. Market Challenges
      • 3.3.1. Introduction of Generic Drugs
    • 3.4. Market Trends
      • 3.4.1. Improved Healthcare Infrastructure, Reimbursements, And Initiatives
      • 3.4.2. An Upsurge in The Number of Clinical Trials to Expand Its Target Patient Base with The Existing Drug Portfolio
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cystic Fibrosis Therapeutic, by Type, Application, Route of Administration, Drug Class, Symptoms and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cystic Fibrosis Therapeutic (Value)
      • 5.2.1. Global Cystic Fibrosis Therapeutic by: Type (Value)
        • 5.2.1.1. Medications
        • 5.2.1.2. Airway Clearance Techniques
        • 5.2.1.3. Pulmonary Rehabilitation
        • 5.2.1.4. Surgery
      • 5.2.2. Global Cystic Fibrosis Therapeutic by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Homecare
        • 5.2.2.3. Speciality Centres
      • 5.2.3. Global Cystic Fibrosis Therapeutic by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Inhalation
      • 5.2.4. Global Cystic Fibrosis Therapeutic by: Drug Class (Value)
        • 5.2.4.1. Pancreatic Enzyme Supplements
        • 5.2.4.2. Mucolytic
        • 5.2.4.3. Bronchodilators
        • 5.2.4.4. CFTR modulators
      • 5.2.5. Global Cystic Fibrosis Therapeutic by: Symptoms (Value)
        • 5.2.5.1. Sputum
        • 5.2.5.2. Wheezing
        • 5.2.5.3. Exercise Intolerance
        • 5.2.5.4. Repeated Lung Infections
        • 5.2.5.5. Inflamed Nasal Passages
        • 5.2.5.6. Recurrent Sinusitis
      • 5.2.6. Global Cystic Fibrosis Therapeutic Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Cystic Fibrosis Therapeutic (Price)
      • 5.3.1. Global Cystic Fibrosis Therapeutic by: Type (Price)
  • 6. Cystic Fibrosis Therapeutic: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Genentech, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Gilead Sciences, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Vertex Pharmaceuticals Incorporated (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AbbVie Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline Plc. (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Allergan plc (Ireland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pharmaxis Ltd. (Australia)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mylan N.V. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cystic Fibrosis Therapeutic Sale, by Type, Application, Route of Administration, Drug Class, Symptoms and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cystic Fibrosis Therapeutic (Value)
      • 7.2.1. Global Cystic Fibrosis Therapeutic by: Type (Value)
        • 7.2.1.1. Medications
        • 7.2.1.2. Airway Clearance Techniques
        • 7.2.1.3. Pulmonary Rehabilitation
        • 7.2.1.4. Surgery
      • 7.2.2. Global Cystic Fibrosis Therapeutic by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Homecare
        • 7.2.2.3. Speciality Centres
      • 7.2.3. Global Cystic Fibrosis Therapeutic by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Inhalation
      • 7.2.4. Global Cystic Fibrosis Therapeutic by: Drug Class (Value)
        • 7.2.4.1. Pancreatic Enzyme Supplements
        • 7.2.4.2. Mucolytic
        • 7.2.4.3. Bronchodilators
        • 7.2.4.4. CFTR modulators
      • 7.2.5. Global Cystic Fibrosis Therapeutic by: Symptoms (Value)
        • 7.2.5.1. Sputum
        • 7.2.5.2. Wheezing
        • 7.2.5.3. Exercise Intolerance
        • 7.2.5.4. Repeated Lung Infections
        • 7.2.5.5. Inflamed Nasal Passages
        • 7.2.5.6. Recurrent Sinusitis
      • 7.2.6. Global Cystic Fibrosis Therapeutic Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Cystic Fibrosis Therapeutic (Price)
      • 7.3.1. Global Cystic Fibrosis Therapeutic by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cystic Fibrosis Therapeutic: by Type(USD Million)
  • Table 2. Cystic Fibrosis Therapeutic Medications , by Region USD Million (2017-2022)
  • Table 3. Cystic Fibrosis Therapeutic Airway Clearance Techniques , by Region USD Million (2017-2022)
  • Table 4. Cystic Fibrosis Therapeutic Pulmonary Rehabilitation , by Region USD Million (2017-2022)
  • Table 5. Cystic Fibrosis Therapeutic Surgery , by Region USD Million (2017-2022)
  • Table 6. Cystic Fibrosis Therapeutic: by Application(USD Million)
  • Table 7. Cystic Fibrosis Therapeutic Hospitals , by Region USD Million (2017-2022)
  • Table 8. Cystic Fibrosis Therapeutic Homecare , by Region USD Million (2017-2022)
  • Table 9. Cystic Fibrosis Therapeutic Speciality Centres , by Region USD Million (2017-2022)
  • Table 10. Cystic Fibrosis Therapeutic: by Route of Administration(USD Million)
  • Table 11. Cystic Fibrosis Therapeutic Oral , by Region USD Million (2017-2022)
  • Table 12. Cystic Fibrosis Therapeutic Inhalation , by Region USD Million (2017-2022)
  • Table 13. Cystic Fibrosis Therapeutic: by Drug Class(USD Million)
  • Table 14. Cystic Fibrosis Therapeutic Pancreatic Enzyme Supplements , by Region USD Million (2017-2022)
  • Table 15. Cystic Fibrosis Therapeutic Mucolytic , by Region USD Million (2017-2022)
  • Table 16. Cystic Fibrosis Therapeutic Bronchodilators , by Region USD Million (2017-2022)
  • Table 17. Cystic Fibrosis Therapeutic CFTR modulators , by Region USD Million (2017-2022)
  • Table 18. Cystic Fibrosis Therapeutic: by Symptoms(USD Million)
  • Table 19. Cystic Fibrosis Therapeutic Sputum , by Region USD Million (2017-2022)
  • Table 20. Cystic Fibrosis Therapeutic Wheezing , by Region USD Million (2017-2022)
  • Table 21. Cystic Fibrosis Therapeutic Exercise Intolerance , by Region USD Million (2017-2022)
  • Table 22. Cystic Fibrosis Therapeutic Repeated Lung Infections , by Region USD Million (2017-2022)
  • Table 23. Cystic Fibrosis Therapeutic Inflamed Nasal Passages , by Region USD Million (2017-2022)
  • Table 24. Cystic Fibrosis Therapeutic Recurrent Sinusitis , by Region USD Million (2017-2022)
  • Table 25. South America Cystic Fibrosis Therapeutic, by Country USD Million (2017-2022)
  • Table 26. South America Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 27. South America Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 28. South America Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 29. South America Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 30. South America Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 31. Brazil Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 32. Brazil Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 33. Brazil Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 34. Brazil Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 35. Brazil Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 36. Argentina Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 37. Argentina Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 38. Argentina Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 39. Argentina Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 40. Argentina Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 41. Rest of South America Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 42. Rest of South America Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 43. Rest of South America Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 44. Rest of South America Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 45. Rest of South America Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 46. Asia Pacific Cystic Fibrosis Therapeutic, by Country USD Million (2017-2022)
  • Table 47. Asia Pacific Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 48. Asia Pacific Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 49. Asia Pacific Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 50. Asia Pacific Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 51. Asia Pacific Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 52. China Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 53. China Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 54. China Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 55. China Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 56. China Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 57. Japan Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 58. Japan Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 59. Japan Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 60. Japan Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 61. Japan Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 62. India Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 63. India Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 64. India Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 65. India Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 66. India Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 67. South Korea Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 68. South Korea Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 69. South Korea Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 70. South Korea Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 71. South Korea Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 72. Taiwan Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 73. Taiwan Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 74. Taiwan Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 75. Taiwan Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 76. Taiwan Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 77. Australia Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 78. Australia Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 79. Australia Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 80. Australia Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 81. Australia Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 82. Rest of Asia-Pacific Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 83. Rest of Asia-Pacific Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 84. Rest of Asia-Pacific Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 85. Rest of Asia-Pacific Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 86. Rest of Asia-Pacific Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 87. Europe Cystic Fibrosis Therapeutic, by Country USD Million (2017-2022)
  • Table 88. Europe Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 89. Europe Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 90. Europe Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 91. Europe Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 92. Europe Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 93. Germany Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 94. Germany Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 95. Germany Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 96. Germany Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 97. Germany Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 98. France Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 99. France Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 100. France Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 101. France Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 102. France Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 103. Italy Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 104. Italy Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 105. Italy Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 106. Italy Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 107. Italy Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 108. United Kingdom Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 109. United Kingdom Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 110. United Kingdom Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 111. United Kingdom Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 112. United Kingdom Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 113. Netherlands Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 114. Netherlands Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 115. Netherlands Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 116. Netherlands Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 117. Netherlands Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 118. Rest of Europe Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 119. Rest of Europe Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 120. Rest of Europe Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 121. Rest of Europe Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 122. Rest of Europe Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 123. MEA Cystic Fibrosis Therapeutic, by Country USD Million (2017-2022)
  • Table 124. MEA Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 125. MEA Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 126. MEA Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 127. MEA Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 128. MEA Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 129. Middle East Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 130. Middle East Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 131. Middle East Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 132. Middle East Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 133. Middle East Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 134. Africa Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 135. Africa Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 136. Africa Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 137. Africa Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 138. Africa Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 139. North America Cystic Fibrosis Therapeutic, by Country USD Million (2017-2022)
  • Table 140. North America Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 141. North America Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 142. North America Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 143. North America Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 144. North America Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 145. United States Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 146. United States Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 147. United States Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 148. United States Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 149. United States Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 150. Canada Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 151. Canada Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 152. Canada Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 153. Canada Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 154. Canada Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 155. Mexico Cystic Fibrosis Therapeutic, by Type USD Million (2017-2022)
  • Table 156. Mexico Cystic Fibrosis Therapeutic, by Application USD Million (2017-2022)
  • Table 157. Mexico Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2017-2022)
  • Table 158. Mexico Cystic Fibrosis Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 159. Mexico Cystic Fibrosis Therapeutic, by Symptoms USD Million (2017-2022)
  • Table 160. Cystic Fibrosis Therapeutic: by Type(USD/Units)
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Cystic Fibrosis Therapeutic: by Type(USD Million)
  • Table 172. Cystic Fibrosis Therapeutic Medications , by Region USD Million (2023-2028)
  • Table 173. Cystic Fibrosis Therapeutic Airway Clearance Techniques , by Region USD Million (2023-2028)
  • Table 174. Cystic Fibrosis Therapeutic Pulmonary Rehabilitation , by Region USD Million (2023-2028)
  • Table 175. Cystic Fibrosis Therapeutic Surgery , by Region USD Million (2023-2028)
  • Table 176. Cystic Fibrosis Therapeutic: by Application(USD Million)
  • Table 177. Cystic Fibrosis Therapeutic Hospitals , by Region USD Million (2023-2028)
  • Table 178. Cystic Fibrosis Therapeutic Homecare , by Region USD Million (2023-2028)
  • Table 179. Cystic Fibrosis Therapeutic Speciality Centres , by Region USD Million (2023-2028)
  • Table 180. Cystic Fibrosis Therapeutic: by Route of Administration(USD Million)
  • Table 181. Cystic Fibrosis Therapeutic Oral , by Region USD Million (2023-2028)
  • Table 182. Cystic Fibrosis Therapeutic Inhalation , by Region USD Million (2023-2028)
  • Table 183. Cystic Fibrosis Therapeutic: by Drug Class(USD Million)
  • Table 184. Cystic Fibrosis Therapeutic Pancreatic Enzyme Supplements , by Region USD Million (2023-2028)
  • Table 185. Cystic Fibrosis Therapeutic Mucolytic , by Region USD Million (2023-2028)
  • Table 186. Cystic Fibrosis Therapeutic Bronchodilators , by Region USD Million (2023-2028)
  • Table 187. Cystic Fibrosis Therapeutic CFTR modulators , by Region USD Million (2023-2028)
  • Table 188. Cystic Fibrosis Therapeutic: by Symptoms(USD Million)
  • Table 189. Cystic Fibrosis Therapeutic Sputum , by Region USD Million (2023-2028)
  • Table 190. Cystic Fibrosis Therapeutic Wheezing , by Region USD Million (2023-2028)
  • Table 191. Cystic Fibrosis Therapeutic Exercise Intolerance , by Region USD Million (2023-2028)
  • Table 192. Cystic Fibrosis Therapeutic Repeated Lung Infections , by Region USD Million (2023-2028)
  • Table 193. Cystic Fibrosis Therapeutic Inflamed Nasal Passages , by Region USD Million (2023-2028)
  • Table 194. Cystic Fibrosis Therapeutic Recurrent Sinusitis , by Region USD Million (2023-2028)
  • Table 195. South America Cystic Fibrosis Therapeutic, by Country USD Million (2023-2028)
  • Table 196. South America Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 197. South America Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 198. South America Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 199. South America Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 200. South America Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 201. Brazil Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 202. Brazil Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 203. Brazil Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 204. Brazil Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 205. Brazil Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 206. Argentina Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 207. Argentina Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 208. Argentina Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 209. Argentina Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 210. Argentina Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 211. Rest of South America Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 212. Rest of South America Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 213. Rest of South America Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 214. Rest of South America Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 215. Rest of South America Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 216. Asia Pacific Cystic Fibrosis Therapeutic, by Country USD Million (2023-2028)
  • Table 217. Asia Pacific Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 218. Asia Pacific Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 219. Asia Pacific Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 220. Asia Pacific Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 221. Asia Pacific Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 222. China Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 223. China Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 224. China Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 225. China Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 226. China Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 227. Japan Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 228. Japan Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 229. Japan Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 230. Japan Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 231. Japan Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 232. India Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 233. India Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 234. India Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 235. India Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 236. India Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 237. South Korea Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 238. South Korea Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 239. South Korea Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 240. South Korea Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 241. South Korea Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 242. Taiwan Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 243. Taiwan Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 244. Taiwan Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 245. Taiwan Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 246. Taiwan Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 247. Australia Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 248. Australia Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 249. Australia Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 250. Australia Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 251. Australia Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 252. Rest of Asia-Pacific Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 253. Rest of Asia-Pacific Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 254. Rest of Asia-Pacific Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 255. Rest of Asia-Pacific Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 256. Rest of Asia-Pacific Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 257. Europe Cystic Fibrosis Therapeutic, by Country USD Million (2023-2028)
  • Table 258. Europe Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 259. Europe Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 260. Europe Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 261. Europe Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 262. Europe Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 263. Germany Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 264. Germany Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 265. Germany Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 266. Germany Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 267. Germany Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 268. France Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 269. France Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 270. France Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 271. France Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 272. France Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 273. Italy Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 274. Italy Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 275. Italy Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 276. Italy Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 277. Italy Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 278. United Kingdom Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 279. United Kingdom Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 280. United Kingdom Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 281. United Kingdom Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 282. United Kingdom Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 283. Netherlands Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 284. Netherlands Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 285. Netherlands Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 286. Netherlands Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 287. Netherlands Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 288. Rest of Europe Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 289. Rest of Europe Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 290. Rest of Europe Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 291. Rest of Europe Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 292. Rest of Europe Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 293. MEA Cystic Fibrosis Therapeutic, by Country USD Million (2023-2028)
  • Table 294. MEA Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 295. MEA Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 296. MEA Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 297. MEA Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 298. MEA Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 299. Middle East Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 300. Middle East Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 301. Middle East Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 302. Middle East Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 303. Middle East Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 304. Africa Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 305. Africa Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 306. Africa Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 307. Africa Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 308. Africa Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 309. North America Cystic Fibrosis Therapeutic, by Country USD Million (2023-2028)
  • Table 310. North America Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 311. North America Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 312. North America Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 313. North America Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 314. North America Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 315. United States Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 316. United States Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 317. United States Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 318. United States Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 319. United States Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 320. Canada Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 321. Canada Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 322. Canada Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 323. Canada Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 324. Canada Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 325. Mexico Cystic Fibrosis Therapeutic, by Type USD Million (2023-2028)
  • Table 326. Mexico Cystic Fibrosis Therapeutic, by Application USD Million (2023-2028)
  • Table 327. Mexico Cystic Fibrosis Therapeutic, by Route of Administration USD Million (2023-2028)
  • Table 328. Mexico Cystic Fibrosis Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 329. Mexico Cystic Fibrosis Therapeutic, by Symptoms USD Million (2023-2028)
  • Table 330. Cystic Fibrosis Therapeutic: by Type(USD/Units)
  • Table 331. Research Programs/Design for This Report
  • Table 332. Key Data Information from Secondary Sources
  • Table 333. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cystic Fibrosis Therapeutic: by Type USD Million (2017-2022)
  • Figure 5. Global Cystic Fibrosis Therapeutic: by Application USD Million (2017-2022)
  • Figure 6. Global Cystic Fibrosis Therapeutic: by Route of Administration USD Million (2017-2022)
  • Figure 7. Global Cystic Fibrosis Therapeutic: by Drug Class USD Million (2017-2022)
  • Figure 8. Global Cystic Fibrosis Therapeutic: by Symptoms USD Million (2017-2022)
  • Figure 9. South America Cystic Fibrosis Therapeutic Share (%), by Country
  • Figure 10. Asia Pacific Cystic Fibrosis Therapeutic Share (%), by Country
  • Figure 11. Europe Cystic Fibrosis Therapeutic Share (%), by Country
  • Figure 12. MEA Cystic Fibrosis Therapeutic Share (%), by Country
  • Figure 13. North America Cystic Fibrosis Therapeutic Share (%), by Country
  • Figure 14. Global Cystic Fibrosis Therapeutic: by Type USD/Units (2017-2022)
  • Figure 15. Global Cystic Fibrosis Therapeutic share by Players 2022 (%)
  • Figure 16. Global Cystic Fibrosis Therapeutic share by Players (Top 3) 2022(%)
  • Figure 17. Global Cystic Fibrosis Therapeutic share by Players (Top 5) 2022(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Genentech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Genentech, Inc. (United States) Revenue: by Geography 2022
  • Figure 21. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 23. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Gilead Sciences, Inc. (United States) Revenue: by Geography 2022
  • Figure 25. Vertex Pharmaceuticals Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 26. Vertex Pharmaceuticals Incorporated (United States) Revenue: by Geography 2022
  • Figure 27. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. AbbVie Inc. (United States) Revenue: by Geography 2022
  • Figure 29. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 31. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 32. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 33. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 34. Allergan plc (Ireland) Revenue: by Geography 2022
  • Figure 35. Pharmaxis Ltd. (Australia) Revenue, Net Income and Gross profit
  • Figure 36. Pharmaxis Ltd. (Australia) Revenue: by Geography 2022
  • Figure 37. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Mylan N.V. (United States) Revenue: by Geography 2022
  • Figure 39. Global Cystic Fibrosis Therapeutic: by Type USD Million (2023-2028)
  • Figure 40. Global Cystic Fibrosis Therapeutic: by Application USD Million (2023-2028)
  • Figure 41. Global Cystic Fibrosis Therapeutic: by Route of Administration USD Million (2023-2028)
  • Figure 42. Global Cystic Fibrosis Therapeutic: by Drug Class USD Million (2023-2028)
  • Figure 43. Global Cystic Fibrosis Therapeutic: by Symptoms USD Million (2023-2028)
  • Figure 44. South America Cystic Fibrosis Therapeutic Share (%), by Country
  • Figure 45. Asia Pacific Cystic Fibrosis Therapeutic Share (%), by Country
  • Figure 46. Europe Cystic Fibrosis Therapeutic Share (%), by Country
  • Figure 47. MEA Cystic Fibrosis Therapeutic Share (%), by Country
  • Figure 48. North America Cystic Fibrosis Therapeutic Share (%), by Country
  • Figure 49. Global Cystic Fibrosis Therapeutic: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Genentech, Inc. (United States)
  • Novartis AG (Switzerland)
  • Gilead Sciences, Inc. (United States)
  • Vertex Pharmaceuticals Incorporated (United States)
  • AbbVie Inc. (United States)
  • GlaxoSmithKline Plc. (United Kingdom)
  • Johnson & Johnson (United States)
  • Allergan plc (Ireland)
  • Pharmaxis Ltd. (Australia)
  • Mylan N.V. (United States)
Select User Access Type

Key Highlights of Report


Nov 2023 215 Pages 56 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cystic Fibrosis Therapeutic Market Quantitative research analysis
Global Cystic Fibrosis Therapeutic Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Cystic Fibrosis Therapeutic market are Genentech, Inc. (United States), Novartis AG (Switzerland), Gilead Sciences, Inc. (United States), Vertex Pharmaceuticals Incorporated (United States), AbbVie Inc. (United States), GlaxoSmithKline Plc. (United Kingdom), Johnson & Johnson (United States), Allergan plc (Ireland), Pharmaxis Ltd. (Australia) and Mylan N.V. (United States), to name a few.
"Improved Healthcare Infrastructure, Reimbursements, And Initiatives " is seen as one of major influencing trends for Cystic Fibrosis Therapeutic Market during projected period 2022-2028.
Medications segment in Global market to hold robust market share owing to "A Rise in Prevalence of Cystic Fibrosis ".

Know More About Global Cystic Fibrosis Therapeutic Market Report?

Have a Query? Click Here

Other Related Reports

Valvular Heart Diseases Treatment Comprehensive Study by Application (Congenital Heart Disease, Valve Stenosis, Valve Regurgitation, Others), Treatment (Surgery, Medication), Route of Administration ...
$ 3750
High Tibial Osteotomy Comprehensive Study by Application (Hospitals, Ambulatory Surgical Centers), Material (Metals, Polymers), Technique (Open Wedge, Closed Wedge, Others) Players and Region - Globa...
$ 3500
Oocyte Cryopreservation Comprehensive Study by Type (Slow-cooling Method, Flash-freezing Process (Vitrification)), Application (25-30-Year-Old Female, 30-35-Year-Old Female, 35-40-Year-Old Female, Ot...
$ 3750
Wound Tissue Analysis Solutions Comprehensive Study by Application (Acute Wounds, Chronic Wounds, Burns, Ulcers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacies, Mail Order Pharma...
$ 3650
Keratosis Pilaris Treatment Comprehensive Study by Type (Rubra, Alba, Rubra Faceii), Treatment (Over-The-Counter, Prescription Medication, Exfoliating, Laser Treatments), Sales Channel (Online Pharma...
$ 3500
Canine Lymphoma Treatment Comprehensive Study by Drug (Alkylating agents, Corticosteroids, Purine Analogs, Antimetabolites, Immune Modulators, Others), Lymphoma (Multicentric lymphoma, Alimentary lym...
$ 3650